C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation.
Hyposensitization therapy for atopic diseases has been conducted for decades but suffered from many problems including anaphylactic reactions. We previously developed a mutant protein of the major mite allergen Derf-2, C8/119S, which showed reduced binding to IgE. The C8/119S mutant was shown to exhibit more efficient hyposensitizing effect than Derf-2 in the animal model of allergic bronchial asthma. In the present study, we indicate that C8/119S exhibits markedly augmented immunogenicity for the proliferation of Derf-2-specific human T cells and T cell clones irrespective of the epitope specificity as compared with Derf-2. Furthermore, C8/119S has induced potent and almost exclusive differentiation of Th1 cells from the peripheral blood of atopic patients in vitro. Neither Ag dosage effect nor absence of B cell-mediated Ag presentation could fully account for these effects. C8/119S has been indicated to lose the characteristic beta-barrel structure as judged by circular dichroism spectroscopic analysis and to polymerize solubly in physiological condition. Heating of Derf-2 also caused less stable molecular aggregation, but it hardly affected the secondary structure and failed to induce such a polarity toward the Th1 cell differentiation. These results have indicated that the degenerate secondary structure of C8/119S leading to stable molecular polymerization is primarily responsible for the marked increase in T cell-immunogenicity and the induction of exclusive Th1 cell differentiation in atopic patients. It has been suggested strongly that the recombinant C8/119S protein can provide an effective Ag with the least risk of anaphylaxis for allergen immunotherapy against house dust mite in human.
Korematsu
S
S
Department of Immunology and Cell Biology, Graduate School of Medicine, and Research Institute for Food Science, Kyoto University, Kyoto, Japan.
Tanaka
Y
Y
Hosoi
S
S
Koyanagi
S
S
Yokota
T
T
Mikami
B
B
Minato
N
N
D000276:Adjuvants, Immunologic / Q000235:genetics; D000485:Allergens / Q000737:chemistry / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D019943:Amino Acid Substitution / Q000235:genetics / Q000276:immunology*; D000818:Animals; D017951:Antigen Presentation / Q000235:genetics; D039741:Antigens, Dermatophagoides; D001402:B-Lymphocytes / Q000276:immunology; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D002999:Clone Cells; D003545:Cysteine / Q000235:genetics; D004306:Dose-Response Relationship, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D006023:Glycoproteins / Q000737:chemistry* / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000097:blood / Q000276:immunology; D008213:Lymphocyte Activation / Q000235:genetics; D008925:Mites / Q000235:genetics / Q000276:immunology*; D016297:Mutagenesis, Site-Directed; D017433:Protein Structure, Secondary; D012694:Serine / Q000235:genetics; D018417:Th1 Cells / Q000166:cytology* / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000485:Allergens; D039741:Antigens, Dermatophagoides; D018984:Epitopes, T-Lymphocyte; D006023:Glycoproteins; D012694:Serine; D003545:Cysteine